Codex provides comprehensive cancer screening using next-generation sequencing (NGS) technology, which help identify genetic mutations associated with 523 cancer-related genes and 9 types of cancer.

Combined with next-generation sequencing, the CoGenesis® Neuro panel screens for 199 conditions, and helps to refine diagnosis for neurodegenerative conditions. The sensitivity and specificity of detecting single nucleotide variations is >99.9%, with a >98% rate for small insertions and deletions of less than 10 base pairs.